Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2 Diabetes In Korea

• Status: Completed
• Trial end date: 2006-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study was designed to evaluate the anti-hypertensive efficacy of lacidipine in hypertensives with Type 2 diabetes and effectiveness on endothelial cell function in Korean population.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Lacidipine

Criteria

Inclusion criteria:

• Newly diagnosed as essential hypertension or not treated in the past 2 weeks(If the subject took medication in the past 2 weeks, a wash-out period of at least 2 weeks will be completed prior to performing screening (week -2) assessments)

• Mean seated SBP at screen visit = 130mmHg (as measured by a mercury sphygmomanometer)

• Type 2 diabetes (American Diabetes Association criteria 2004) and HbA1C <11%

• Agree to practice acceptable contraceptive measures during the study, and for 30 days after the last dose of study medication is taken if the subject a female of child-bearing potential

• Provide written informed consent

Exclusion criteria:

• Mean seated SBP of > 180 mmHg

• Known or suspected secondary hypertension

• Anemia defined by haemoglobin concentration < 10.0 g/dL

• Hemoglobinopathy or peripheral vascular disease

• Clinically significant renal or hepatic disease (i.e., subjects with serum creatinine = 2.0 mg/dL; Alanine aminotransferase, Aspartate aminotransferase, total bilirubin, or alkaline phosphatase > 2.5 times the upper limit of the normal reference range)

• Unstable or severe angina, coronary insufficiency, or any congestive heart failure requiring pharmacologic treatment

• Chronic disease requiring intermittent or chronic treatment with oral, intravenous, or intra-articular corticosteroids (i.e. only use of topical, inhaled or nasal corticosteroids is permissible)

• Female who is lactating, pregnant, or planning to become pregnant

• clinically significant abnormality identified at screening which in the judgement of the investigator makes the subject unsuitable for inclusion in the study (e.g. physical examination, laboratory tests, or electrocardiogram etc.)

• Acute or chronic metabolic acidosis or a history of diabetic ketoacidosis